KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK), Monday announced that Health Canada has approved KEYTRUDA in combination with cisplatin-based chemoradiotherapy for patients with FIGO 2014 Stage III-IVA cervical cancer.
The decision follows results from the Phase III KEYNOTE-A18 trial, which showed that adding KEYTRUDA to CRT significantly improved progression-free survival and overall survival versus CRT alone.
MRK is currently trading at $79.22, down $0.74 or 0.93 percent on the New York stock Exchange.
Copyright(c) 2025 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
© 2025 AFX News
